FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W144791431> ?p ?o ?g. }

• W144791431 endingPage "639" @default.
• W144791431 startingPage "629" @default.
• W144791431 abstract "A letter by Zheng and Xu in this issue of JMCP spotlights a consensus statement on off-label medication use, written by 20 senior chief pharmacists from 17 hospitals in the Guangdong province of China in March 2010. The statement’s provocative recommendations include the imposition of requirements that (a) the off-label drug should be “irreplaceable for treatment of the patient,” that is, no drug labeled for the indication is available; (b) the off-label use must be “submitted and approved by the hospital’s pharmacotherapy committee and hospital ethics committee” except in emergency situations; and (c) informed consent for off-label use must be obtained from the patient or a legal representative. The letter comes on the heels of nearly 2 years of heightened debate in the United States over the use of and payment for drugs prescribed to treat indications for which they are not approved by the U.S. Food and Drug Administration (FDA). Triggered by several factors—including U.S. Department of Justice (DOJ) litigation against pharmaceutical companies for off-label promotion, new guidance for “Good Reprint Practices” promulgated by the FDA in January 2009 to clarify the types of medical literature deemed acceptable for distribution to physicians, and the passage of the Affordable Care Act of 2010—the controversy has drawn the attention of numerous stakeholders with different and sometimes sharply conflicting perspectives. In March 2009, we noted that positions on off-label drug use taken by different federal agencies appeared inconsistent, with the DOJ’s legal actions against off-label marketing becoming increasingly intense even as the FDA slightly relaxed its stance against the practice and the Centers for Medicare & Medicaid Services (CMS) expanded Medicare coverage for off-label use of chemotherapeutic drugs. Since that time, the controversy has intensified, with stakeholders adopting positions that seem to allow little or no ground for compromise." @default.
• W144791431 created "2016-06-24" @default.
• W144791431 creator A5034909286 @default.
• W144791431 creator A5085074084 @default.
• W144791431 date "2010-10-01" @default.
• W144791431 modified "2023-09-25" @default.
• W144791431 title "Regulatory Actions on the Off-Label Use of Prescription Drugs: Ongoing Controversy and Contradiction in 2009 and 2010" @default.
• W144791431 cites W1990068188 @default.
• W144791431 cites W1995713263 @default.
• W144791431 cites W2000336408 @default.
• W144791431 cites W2015078225 @default.
• W144791431 cites W2029541454 @default.
• W144791431 cites W2041431725 @default.
• W144791431 cites W2103563357 @default.
• W144791431 cites W2103928570 @default.
• W144791431 cites W2110338735 @default.
• W144791431 cites W2126275851 @default.
• W144791431 cites W2128380434 @default.
• W144791431 cites W2167224460 @default.
• W144791431 cites W2183047108 @default.
• W144791431 cites W2277776880 @default.
• W144791431 cites W2033172977 @default.
• W144791431 doi "https://doi.org/10.18553/jmcp.2010.16.8.629" @default.
• W144791431 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20866167" @default.
• W144791431 hasPublicationYear "2010" @default.
• W144791431 type Work @default.
• W144791431 sameAs 144791431 @default.
• W144791431 citedByCount "8" @default.
• W144791431 countsByYear W1447914312012 @default.
• W144791431 countsByYear W1447914312015 @default.
• W144791431 countsByYear W1447914312016 @default.
• W144791431 countsByYear W1447914312017 @default.
• W144791431 countsByYear W1447914312019 @default.
• W144791431 countsByYear W1447914312020 @default.
• W144791431 countsByYear W1447914312022 @default.
• W144791431 crossrefType "journal-article" @default.
• W144791431 hasAuthorship W144791431A5034909286 @default.
• W144791431 hasAuthorship W144791431A5085074084 @default.
• W144791431 hasConcept C111472728 @default.
• W144791431 hasConcept C138885662 @default.
• W144791431 hasConcept C177713679 @default.
• W144791431 hasConcept C188313352 @default.
• W144791431 hasConcept C2426938 @default.
• W144791431 hasConcept C2776728590 @default.
• W144791431 hasConcept C71924100 @default.
• W144791431 hasConcept C98274493 @default.
• W144791431 hasConceptScore W144791431C111472728 @default.
• W144791431 hasConceptScore W144791431C138885662 @default.
• W144791431 hasConceptScore W144791431C177713679 @default.
• W144791431 hasConceptScore W144791431C188313352 @default.
• W144791431 hasConceptScore W144791431C2426938 @default.
• W144791431 hasConceptScore W144791431C2776728590 @default.
• W144791431 hasConceptScore W144791431C71924100 @default.
• W144791431 hasConceptScore W144791431C98274493 @default.
• W144791431 hasIssue "8" @default.
• W144791431 hasLocation W1447914311 @default.
• W144791431 hasLocation W1447914312 @default.
• W144791431 hasOpenAccess W144791431 @default.
• W144791431 hasPrimaryLocation W1447914311 @default.
• W144791431 hasRelatedWork W1609679782 @default.
• W144791431 hasRelatedWork W1969591584 @default.
• W144791431 hasRelatedWork W1999367008 @default.
• W144791431 hasRelatedWork W2002050335 @default.
• W144791431 hasRelatedWork W2049957979 @default.
• W144791431 hasRelatedWork W2054596156 @default.
• W144791431 hasRelatedWork W2092643762 @default.
• W144791431 hasRelatedWork W2133678577 @default.
• W144791431 hasRelatedWork W3011969312 @default.
• W144791431 hasRelatedWork W3198442264 @default.
• W144791431 hasVolume "16" @default.
• W144791431 isParatext "false" @default.
• W144791431 isRetracted "false" @default.
• W144791431 magId "144791431" @default.
• W144791431 workType "article" @default.